Angiogenesis is considered a hallmark of multiple myeloma (MM) progression. In the present study, we evaluated the morphological and functional features of endothelial cells (ECs) derived from bone marrow (BM) of patients affected by MM (MMECs). We found that MMECs compared with normal BM ECs (BMECs) showed increased expression of syndecan-1. Silencing of syndecan-1 expression by RNA interference technique decreased in vitro EC survival, proliferation and organization in capillary-like structures. In vivo, in severe combined immunodeficient mice, syndecan-1 silencing inhibited MMEC organization into patent vessels. When overexpressed in human umbilical vein ECs and BMECs, syndecan-1 induced in vitro and in vivo angiogenic effects. Flow-cytometric analysis of MMECs silenced for syndecan-1 expression indicated a decreased membrane expression of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2). Immunoprecipitation and confocal analysis showed colocalization of VEGFR-2 with syndecan-1. Absence of nuclear translocation of VEGFR-2 in syndecan-1-knockdown cells together with the shift from perinuclear localization to recycling compartments suggest a role of syndecan-1 in modulation of VEGFR-2 localization. This correlated with an in vitro decreased VEGF-induced invasion and motility. These results suggest that syndecan-1 may contribute to the highly angiogenic phenotype of MMECs by promoting EC proliferation, survival and modulating VEGF --VEGFR-2 signalling.
INTRODUCTION
Multiple myeloma (MM) is a haematological malignancy characterized by accumulation of clonal malignant plasma cells predominantly within the bone marrow (BM) 1 and by increased BM neovascularization. 2 --4 There is a direct correlation between BM microvessel density and parameters of disease progression. 5 Moreover, increased BM vascularization in MM patients is correlated with a poor prognosis. 6 --8 Endothelial cells (ECs) derived from MM patients significantly differ from normal microvascular ECs in terms of proliferation, phenotype, morphology and capillarogenic activity. 9 --12 In patients affected by MM syndecan-1, a heparan sulphate proteoglycan, is overexpressed by myeloma cells in the BM and peripheral blood. 13, 14 The high serum level of shed syndecan-1 has been associated with an unfavourable prognosis. 15, 16 The presence of heparin sulphate chains allows cell-to-cell and cell-to-extracellular matrix interactions. Moreover, syndecan-1 is able to interact with several growth factors, including pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblastic growth factor. 17 Syndecan-1 seems to be able to modulate neovascularization by increasing the local concentration of growth factors, 18 by mediating their binding to specific receptors 19 --21 and/or by interacting directly with the receptors. 22 --25 Expression of syndecan is often altered in cancer, 26, 27 and several studies suggest that syndecan-1 expression promotes the growth of several malignancies, including MM. 28 --31 The aim of the present study was to investigate whether syndecan-1 was overexpressed on the surface of ECs derived from the BM of MM patients (MMECs) as compared with normal BM ECs (BMECs). Moreover, we investigated the functional implication of syndecan-1 expression by MMECs in MM angiogenesis. Using an RNA interference approach, to knockdown syndecan-1 expression, we determinate the involvement of syndecan-1 in MMEC proliferation, resistance to apoptosis, the ability to invade the basal membrane, in vitro (2012) 26, 1082 --1091. and in vivo angiogenic properties, and responsiveness to VEGF stimulation. 
MATERIALS AND METHODS

Cell lines
Primary microvascular EC lines from the BM of healthy donor (BMECs) or MM patients (MMECs) were isolated. Briefly, BM aspirates were centrifuged on Ficoll (Biochrom AG, Berlin, Germany) gradient centrifugation and ECs were isolated from mononuclear cells by using anti-CD31Ab coupled to magnetic beads by magnetic cell sorting (MACS system, Miltenyi Biotec, Auburn, CA, USA). Cells were recovered and transferred to six-well plates, previously coated with Endothelial Cell Attachment Factor (Sigma, St Louis, CA, USA) in 3-ml complete medium per well. Primary cultures of human umbilical vein ECs (HUVECs) were isolated as described previously. 32 Cell
Syndecan-1 overexpression
The pOTB7 plasmid, containing the full coding region of human SDC1, was purchased from Open Biosystems (Huntsville, AL, USA). The plasmid was purified according to the Qiagen Plasmid mini kit protocol (Qiagen GmbH, Hilden, Germany) and sent to Vector BioLabs (Philadelphia, PA, USA) for AD-FRP-h synedecan-1 adenoviral vector construction. For virus infection, BMECs or HUVECs were seeded at a density of 2 Â 10 5 cells/well in six-well plates and infected with 0.5 Â 10 6 IFU/p.f.u. (infectious unit/ml) of virus preparation. After overnight absorption at 37 1C, the viral infection medium was removed, cells were washed twice with phosphate-buffered saline and fresh medium was added. Syndecan-1 overexpression was subsequently analysed by flow cytometry and quantitative reverse transcription-PCR (qRT-PCR).
Cell proliferation and apoptosis assays 
Zymographic analysis
Gelatinolytic activity of matrix metalloproteinases (MMPs) was assessed under non-reducing conditions using a modified sodium dodecyl sulphate-PAGE. The supernatant, obtained after 24 h of starvation, was mixed with Laemmli buffer and loaded into an 8% polyacrylamide gel copolymerized with 1 mg/ml gelatin (Sigma). Electrophoresis and gel staining were performed as described previously. 33 An aliquot of RPMI with 10% FBS was used to determine the molecular weight of the gelatinase.
In vitro and in vivo angiogenesis assays
In vitro angiogenesis was studied by seeding cells on reduced growth factor Matrigel-coated plates and in vivo angiogenesis by subcutaneous injection of cells within Matrigel into severe combined immunodeficient (SCID) mice as described under Supplementary Materials and methods.
Immunoprecipitation
Cells were serum-starved for 24 h and then lysed in cold DIM buffer (50 mM Pipes (pH 6.8), 100 mM NaCl, 5 mM MgCl 2 , 300 mM sucrose, 5 mM EGTA) plus 1% Triton X-100 and a mixture of protease inhibitors (Sigma). Equal amount (1 mg) of proteins was immunoprecipitated using protein-A/G plus --agarose beads (Santa Cruz Biotechnology) pre-coated by an anti-syndecan-1 or a VEGFR-2 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (each at 2 mg). Bound proteins were washed several times in DIM buffer and resuspended in boiling Laemmli buffer. Resuspended proteins were then subject to electrophoresis on Any kD sodium dodecyl sulphate-polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA), transferred to nitrocellulose and probed with the appropriate antibody, followed by a horseradish peroxidase-conjugated secondary antibody (Sigma) and an enhanced chemiluminescent substrate (Thermo Scientific, Waltham, MA, USA).
EC migration assays
Details on EC migration assays are provided under Supplementary Materials and methods.
RESULTS
Isolation and characterization of MMECs
MMECs and BMECs were isolated, respectively, from BM aspirates of 10 different MM patients at diagnosis and four different healthy donors. Flow-cytometric analysis showed that all the cell lines isolated were endothelial; more than 95% cells expressed UEA-1, VWF and CD144 (VE-cadherin) but not monocyte --macrophage (CD14), leukocyte (CD45), plasma cell (CD38) markers and mesenchymal cell markers (vimentin) (Figures 1a and b) . The MMECs phenotype was analysed in comparison with BMECs (Supplementary Table 3 ). Both cell types expressed the same levels of CD44, CD90, CD29, CD105, CD144 (VE-cadherin), CD146, VEGFR-1 and VEGFR-3 and showed absence of CD154, CD34 and CD133 expression. MMECs showed greater expression of CD40, UEA-1, VEGFR-2 and, in particular, CD138 (syndecan-1) than BMECs (Supplementary Table 3 ). The higher expression of syndecan-1 by MMECs was not only at the protein level but also at the mRNA level, as confirmed by qRT-PCR (Figures 1c and d) . At variance between MMECs and BMECs, HUVECs did not express syndecan-1 protein and mRNA. For this reason HUVECs were used as control for studies aimed to investigate the function of syndecan-1.
Syndecan-1 expression promotes proliferation and protects against apoptosis To analyse the role of syndecan-1 expression on MMECs, we used an RNA interference approach. A pool of syndecan-1 siRNAs and, as control, an scr-siRNA was transiently transfected into MMECs to knock down syndecan-1 expression. Syndecan-1 siRNA, but not scr-siRNA, transfection effectively inhibited syndecan-1 mRNA and protein expression in MMECs (see Supplementary Figure 1 and Supplementary Materials and methods). Then, to study the effect of syndecan-1 knockdown on EC apoptosis and proliferation, we compared the growth and apoptosis resistance of MMECs using an MMEC syndecan-1 siRNA and, as control, an MMEC scr-siRNA. An additional control included HUVECs. As shown in Figure 2a , after 48 h of culture with decreasing serum levels, MMECs proliferated significantly more than HUVECs. Transfection with syndecan-1 siRNA, but not scr-siRNA, reduced this increase to levels comparable to that of HUVECs. As internal control, cells were grown in culture media (EBM 10% FBS) (Figure 2a) . Moreover, to evaluate the effect of syndecan-1 expression on apoptosis resistance, HUVECs, MMECs, MMEC syndecan-1 siRNA and, as control, MMEC scr-siRNA, were grown for 24 h in the absence of serum ( Figure 2b ). As shown in Figure 2b , MMECs showed less sensitivity to apoptosis, induced by serum deprivation, compared with HUVECs. Knockdown of syndecan-1 expression (MMEC syndecan-1 siRNA) determinated an increase in sensitivity to apoptosis, even in the presence of serum. These results suggest that expression of syndecan-1 on MMECs has a role in cell proliferation and resistance to apoptosis. These effects seemed to be independent from a reduced cell adhesion of syndecan-1-knockdown cells, as both MMECs and MMEC syndecan-1 siRNA showed the same ability to adhere to gelatin-coated plates on which proliferation and apoptosis assays were performed (data not shown).
To explore the mechanism involved in proliferation inhibition and apoptosis induction by syndecan-1 silencing, we investigated, by PCR arrays, human cell-cycle and apoptosis pathways. The results showed changes in genes involved in G 2 /M transition and the M phase. GTP-binding RAS-like-3 was highly expressed by syndecan-1-knockdown cells as compared with MMECs, whereas, the levels of baculoviral inhibitor of apoptosis repeat containing-5 (BIRC5), cyclin-B1 (CCNB1), CDC28 protein kinase-regulatory subunit-1B (CKS1B), CDC28 protein kinase-regulatory subunit-2 (CKS2), cyclin-B2 (CCNB2), cyclin-dependent kinase-1 (CDK1), cell division cycle-20 homologue (CDC20) and antigen identified by monoclonal antibody Ki-67 (MKi67) were decreased. These genes were verified by qRT-PCR and were all significantly changed as compared with MMECs ( Figure 3a) . These results indicated an arrest of syndecan-1-knockdown cells in G 2 /M transition and in the M phase. The apoptosis array revealed that syndecan-1-knockdown cells expressed elevated level of pro-apoptotic genes such as BCL2-associated X protein (BAX) and tumor necrosis factor receptor superfamily member-21 (TNFRSF21), whereas antiapoptotic genes, such as BCL2-like-10 (BCL2L10), baculoviral inhibitor of apoptosis repeat containing-3 (BIRC3) and nucleolar protein-3 (NOL3) were downregulated. qRT-PCR confirmed significant variation of BAX, TNFRSF21, BCL2L10, BIRC3 and NOL3 expression (Figure 3b ). Interestingly, syndecan-1-knockdown cells had low expression of BIRC3, whose encoded protein inhibits apoptosis induced by serum deprivation. This suggests that low membrane expression of syndecan-1 sensitizes the cells to apoptosis induced by serum deprivation. The profile of gene analysis of BMECs, when compared with that of MMECs, showed a significant reduction of genes involved in M phase and a decrease of anti-apoptotic genes and increase of pro-apoptotic genes (Figures 3a and b) .
Syndecan-1 expression promotes Matrigel invasion
We analysed MMEC basal membrane invasiveness and its dependence on syndecan-1 expression. Thus, we compared HUVECs, MMECs, MMEC syndecan-1 siRNA and, as control, the MMEC scr-siRNA for ability to invade Matrigel in vitro. The results showed that MMECs, as compared with HUVECs, showed enhanced ability to invade Matrigel, whereas the MMEC syndecan-1 siRNA, but not the MMEC scr-siRNA, showed a statistically significant decrease of this ability (Figure 4a ). To evaluate whether syndecan-1 expression correlated with MMP secretion, we tested the gelatinolytic ability of HUVECs, MMECs, MMEC scr-siRNA and MMEC syndecan-1 siRNA supernatants. MMECs, MMEC scr-siRNA and HUVECs secrete activated MMP-2 (72-kDa form) and MMP-9 (83-kDa form). The MMEC values were, on average, 3 and 4 times higher for MMP-2 and MMP-9, respectively, as demonstrated previously 11 and there were no differences between MMECs and MMEC scr-siRNA (data not shown). We detected a decrease in both the 72 and 83-kDa bands of about 1.5 and 3 times, respectively, in the MMEC syndecan-1 siRNA supernatant as compared with the MMEC supernatant ( Figure 4b ). The presence of reduced invasion and decrease of the active form of MMP-2 and MMP-9 in MMEC syndecan-1 siRNA suggests a possible role of syndecan-1 in the regulation of MMP secretion and in vitro MMEC invasion ability. Syndecan-1 can promote cell adhesion and invasion into the BM extracellular matrix. 34 In this contest we analysed MMECs and MMEC syndecan-1 siRNA ability to adhere to Matrigel. After 2 h of incubation the MMEC syndecan-1 siRNA showed decreased adhesion of about 40% compared with MMECs ( Figure 4c ). 
Syndecan-1 expression mediates VEGF --VEGFR-2 signalling
Analyzing the phenotype of MMECs versus syndecan-1-knockdown MMECs we found that syndecan-1 silencing determinated a decrease in the expression of VEGFR-2 ( Figure 7Aa ). Conversely, induced syndecan-1 overexpression on BMECs and HUVECs increased VEGFR-2 protein expression (Figure 7Ab and c) . Thus, we analysed the possibility that sydecan-1 could physically interact with VEGFR-2 and form an active complex at the membrane of MMECs. We observed that an anti-syndecan-1 antibody was able to precipitate two proteins of about 200 and 230 kDa, respectively, corresponding to two of the three isoforms of VEGFR-2, as shown by anti-VEGFR-2 immunoblots ( Figure 7B , top). The specificity of this interaction was demonstrated by coimmunoprecipitation experiments using an antibody against VEGFR-2 ( Figure 7B , bottom). Colocalization between VEGFR-2 and syndecan-1 in MMECs was also observed also by confocal microscopy ( Figure 7C ). These results indicated that syndecan-1 was associated to VEGFR-2. We then hypothesized that VEGFR-2 localization might be regulated by syndecan-1 expression. As seen by flow-cytometric analysis ( Figure 7Aa ) and confocal microscopy ( Figure 7C ), syndecan-1 silencing decreased the surface expression of VEGFR-2. As shown by immunofluorescence in permeabilized cells, the intracellular distribution of VEFGR-2 in MMECs was predominantly peri-nuclear, whereas in syndecan-1-knockdown cells it was cytoplasmic ( Figure 7D ) and colocalized with Rasrelated in brain-11 (Rab11), a marker of the long-loop recycling pathway ( Figure 7E ). Similar results were observed with the Early Endosome Antigen-1 (EEA1) (data not shown). By contrast, in MMECs VEGFR-2, which was mainly perinuclear ( Figure 7D ), showed only minimal colocalization with the recycling markers ( Figure 7E ). No colocalization of VEGFR-2 was seen with either the Golgi Membrane protein-130 (GM130) or the marker of the TransGolgi Network-38 (TGN38) (data not shown). Moreover, nuclear translocation of VEGFR-2 after VEGF stimulation was almost completely abrogated in syndecan-1-knockdown cells ( Figure 7F) . A reduced synthesis of VEGFR-2 was also suggested by its reduced transcription as shown in Figure 7G .
Thus, we analysed the effect of syndecan-1 silencing in VEGFinduced motility. In basal condition, all cells analysed were found to remain steady for the whole period of observation, never exceeding an average speed of 11 --13 ìm/h. Stimulation with VEGF significantly enhanced HUVEC and MMEC migration (Figures 8a  and b) . In particular, MMECs showed a major response to the VEGF stimulus than HUVECs, as they reached a speed of approximately 26 mm/h, whereas HUVEC motility was about 19 mm/h. Knockdown of syndecan-1 expression on MMECs abrogated VEGF-dependent EC migration, reducing the speed average to basal levels ( Figures  8a and b) . The effects persisted for the whole period of observation (Figure 8a ). Moreover, we analysed the effect of syndecan-1 knockdown on invasion in the presence of 25 ng/ml VEGF. After 48 h, both HUVECs and MMECs showed an increased ability to invade Matrigel in the presence of VEGF, as compared with the basal condition (Figure 8c) . Conversely, syndecan-1 knockdown abrogated the VEGF-induced invasiveness of MMECs to levels comparable to that of HUVECs (Figure 6e) .
DISCUSSION
In the present study, we found that ECs obtained from the BM of patients with MM overexpressed syndecan-1 and we provide evidence that its expression contributes to their proliferative, apoptosis-resistant, pro-invasive and pro-angiogenic phenotype.
Previous studies suggested that overexpression of syndecan-1 by MM cells correlates with disease progression. 30,35 --38 We here demonstrated that also MMECs overexpress this proteoglycan in respect to ECs derived from normal BM. As the functional significance of syndecan-1 expression by MMECs has not been investigated before, we examined its role in angiogenesis. It has been suggested that syndecan-1-retaining heparin-binding factors within the BM microenvironment may provide a support for the growth and survival of tumor plasma cells. 34, 39 Here we suggested that syndecan-1 could be also involved in the modulation of the growth and survival of ECs within the BM microenvironment. In fact, knockdown of syndecan-1 expression by RNA interference resulted in arrest of the cell in G 2 /M transition and M phase, and enhanced the sensitivity of MMECs to apoptosis. Moreover, in the present study we found that syndecan-1 expression correlated with enhanced in vitro and in vivo angiogenic activity. Indeed, downregulation of syndecan-1 was associated with a decreased in vitro capillary like-structure and in vivo angiogenic network by MMECs associated with a decrease of spontaneous Matrigel invasion. These results suggest that syndecan-1 can promote endothelial invasion into the extracellular matrix directly or indirectly regulating MMPs. We also showed decreased adherence of syndecan-1-knockdown MMECs to Matrigel. This result suggests that syndecan-1, by mediating also cell-to-matrix interactions, promoted cell adhesion and invasion into the extracellular matrix. On the other hand, we demonstrated that acquisition by HUVECs and overexpression in BMECs of syndecan-1 induced a phenotype similar to that of MMECs. In fact, HUVECs and BMECs overexpressing syndecan-1 showed an enhanced ability to form capillary-like structure in vitro. Moreover, HUVECs and BMECs overexpressing syndecan-1 acquired a highly angiogenic phenotype when injected in Matrigel in SCID mice. These data suggest that syndecan-1 expression may influence the angiogenic behaviour of ECs contributing to the acquisition of an activated phenotype. This phenotype may depend not only on an enhanced cell-to-cell interaction and production of MMPs, but also on an enhanced response to pro-angiogenic factors. Indeed, comparing the MMEC phenotype versus that of syndecan-1-knockdown MMECs, we observed a decrease of VEGFR-2 surface expression. Immunoprecipitation studies demonstrated a physical interaction between syndecan-1 and VEGFR-2. This observation is consistent with the ability of syndecan-1 to interact with this growth factor receptor. 22, 23 Moreover, we found that syndecan-1 silencing correlated with a reduced ability of MMECs to respond to VEGF. This may depend on a modulatory role of syndecan-1 on VEGFR-2 expression. Indeed, after syndecan-1 silencing reduced VEGFR-2 surface expression and its preeminent localization within the cytoplasm in association with the endosomal recycling compartments was observed. These results suggest that the syndecan-1 expression prevents the intracellular recycling of VEGFR-2 and is relevant for maintaining the receptor within the plasma membrane, thus allowing interaction with its ligand. Moreover, nuclear translocation of VEGFR-2 after interaction with VEGF, 41, 42 which has been suggested to regulate its synthesis, 43 was almost completely absent in syndecan-1-knockdown cells. In agreement with this hypothesis, we observed a reduced expression of VEGFR-2 mRNA in syndecan-1-knockdown cells.
Previous studies demonstrated that syndecan-1 expression by plasma cells and its soluble form have a prognostic value. 16, 30 Therefore, syndecan-1 has been considered a potential therapeutic target in MM. Several studies have successfully developed different syndecan-1 inhibition strategies. 35, 37, 38, 44, 45 A phase-I clinical study is ongoing using a cytotoxin-conjugated antibody against syndecan-1 (BT062). 46 The present finding that also MMECs express high levels of syndecan-1 with functional relevance in tumor angiogenesis extends the potential beneficial effect of syndecan-1 targeting against MM progression, acting both on the tumoral cell and the BM microenvironment. However, it remains to be determined whether syndecan-1 blockade might interfere with physiological angiogenesis. Further studies are needed to investigate whether syndecan-1 expression may define an angiogenic profile and correlate with cytogenetics and patient outcome.
In conclusion, the results of the present study provide a novel insight into regulation of MM angiogenesis by syndecan-1 and suggest that impairment of physiological function of syndecan-1 could be an interesting therapeutic approach for treatment of this malignancy. 
